In this episode of the Oncology Brothers podcast, we kick off a three-part CME series focused on small cell lung cancer (SCLC). We are joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at Fox Chase Cancer Center, to discuss the evolving treatment landscape for SCLC, particularly in light of recent data presented at ASCO 2025.
We began by setting the stage for our discussion, highlighting the challenges of treating small-cell lung cancer, where survival rates have historically been limited. Dr. Borghaei outlined the current standard of care for limited-stage disease is concurrent chemoradiation therapy followed by immunotherapy consolidation.
When focusing on extensive stage disease, he emphasized the recent advancements that have led to improved overall survival rates, including the introduction of lurbinectedin as a maintenance therapy and the use of bispecific antibodies like tarlatamab in later lines of treatment.
Dr. Borghaei shared his treatment algorithm for extensive-stage SCLC, noting the importance of patient selection based on performance status and tolerance to previous therapies. He discussed the incremental benefits of new treatments, acknowledging that while improvements in survival may only be a few months, they are significant in the context of this devastating disease.
We also delved into the role of growth factors in managing side effects and the importance of balancing toxicity with potential benefits. Dr. Borghaei provided insights into the real-world application of these therapies, including considerations for patients with CNS involvement.
As we wrapped up, we reflected on the promising future of SCLC treatment, particularly with the potential for immune-based therapies to provide longer-term survival benefits. Dr. Borghaei expressed optimism about ongoing research and the possibility of tailoring treatments to specific patient subtypes.
Join us for the next episodes in this series, where we will focus on managing treatment side effects and exploring unmet needs in the field of small-cell lung cancer.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc